DT2216 synergizes with AZA, ruxolitinib (Ruxo), and venetoclax (VEN) in inhibiting JAK2-mut AML cell lines. (A) Viability of paired SET2 Pa and Ruxo-Re AML cell lines treated with AZA and/or DT2216 at the indicated concentrations for 72 hours. (B) Western blots showing BCL-xL degradation in SET2 cells treated with 1 μM DT2216 and/or AZA for 24 hours. (C) Viability of paired SET2 Pa and Ruxo-Re AML cell lines treated with Ruxo and/or DT2216 at the indicated concentrations for 72 hours. (D) Western blots showing BCL-xL degradation in SET2 cells treated with 1 μM DT2216 and/or Ruxo for 24 hours. (E) Viability of SET2 Pa and Ruxo-Re AML cell lines treated with VEN and/or DT2216 at the indicated concentrations for 72 hours. (F) Western blots showing BCL-xL degradation in SET2 cells treated with 1.5 μM DT2216 and/or 3 μM VEN for 24 hours. β-Actin was used as the loading control for the western blot. Comb, combination.